Search for other papers by Nelma Veronica Marques in
Google Scholar
PubMed
Search for other papers by Luiz Eduardo Armondi Wildemberg in
Google Scholar
PubMed
Search for other papers by Monica R Gadelha in
Google Scholar
PubMed
Introduction Pasireotide long-acting release is a multireceptor-targeted somatostatin receptor ligand (SRL) approved to treat adult patients with acromegaly ( 1 ). In patients, this second-generation SRL has been shown to be effective in
Search for other papers by Elena Valassi in
Google Scholar
PubMed
Search for other papers by Natalia García-Giralt in
Google Scholar
PubMed
Search for other papers by Jorge Malouf in
Google Scholar
PubMed
Search for other papers by Iris Crespo in
Google Scholar
PubMed
Search for other papers by Jaume Llauger in
Google Scholar
PubMed
Search for other papers by Adolfo Díez-Pérez in
Google Scholar
PubMed
Search for other papers by Susan M Webb in
Google Scholar
PubMed
of bone matrix and bone mass ( 1 ). Acromegaly (ACRO) is a rare disease caused by excessive GH production from a pituitary adenoma ( 4 ). Chronic elevation of GH and IGF1 in ACRO is associated with severe cardiovascular, respiratory and metabolic
Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France
Search for other papers by Hélène Lasolle in
Google Scholar
PubMed
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France
Search for other papers by Amandine Ferriere in
Google Scholar
PubMed
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France
Centre de Pathologie et de Neuropathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
Search for other papers by Alexandre Vasiljevic in
Google Scholar
PubMed
Service d’anatomo-pathologie, Hopital Pellegrin, CHU de Bordeaux, Bordeaux, France
Search for other papers by Sandrine Eimer in
Google Scholar
PubMed
Search for other papers by Marie-Laure Nunes in
Google Scholar
PubMed
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France
Search for other papers by Antoine Tabarin in
Google Scholar
PubMed
Introduction Acromegaly is predominantly caused by a growth hormone (GH)-secreting pituitary adenoma resulting in excessive insulin-like growth factor-I (IGF-I) secretion that is responsible for numerous co-morbidities, reduced quality of life
Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA
Pituitary Center, Oregon Health & Science University, Portland, Oregon, USA
Search for other papers by Elena V Varlamov in
Google Scholar
PubMed
Search for other papers by Dan Alexandru Niculescu in
Google Scholar
PubMed
Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA
Pituitary Center, Oregon Health & Science University, Portland, Oregon, USA
Search for other papers by Swechya Banskota in
Google Scholar
PubMed
Search for other papers by Simona Andreea Galoiu in
Google Scholar
PubMed
Search for other papers by Catalina Poiana in
Google Scholar
PubMed
Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA
Pituitary Center, Oregon Health & Science University, Portland, Oregon, USA
Search for other papers by Maria Fleseriu in
Google Scholar
PubMed
Introduction Acromegaly is a rare disease that is caused by excessive growth hormone (GH) secretion by a pituitary adenoma ( 1 , 2 , 3 ). The clinical picture of active acromegaly is characterized by a combination of symptoms, signs, and
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by Liliya Rostomyan in
Google Scholar
PubMed
Search for other papers by Daniela Betea in
Google Scholar
PubMed
Search for other papers by Jean-François Bonneville in
Google Scholar
PubMed
Department of Pathological Cytology and Anatomy, Foch Hospital, Paris, France
Search for other papers by Chiara Villa in
Google Scholar
PubMed
Search for other papers by Natalia S Pellegata in
Google Scholar
PubMed
Search for other papers by Beatrice Waser in
Google Scholar
PubMed
Search for other papers by Jean-Claude Reubi in
Google Scholar
PubMed
Search for other papers by Catherine Waeber Stephan in
Google Scholar
PubMed
Search for other papers by Emanuel Christ in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
Introduction Acromegaly is a rare, classical endocrine disorder that is due to chronic excess secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) that has a prevalence of 1 in 8000–14,000 of the population ( 1 , 2 , 3
Search for other papers by Gudmundur Johannsson in
Google Scholar
PubMed
Search for other papers by Martin Bidlingmaier in
Google Scholar
PubMed
Search for other papers by Beverly M K Biller in
Google Scholar
PubMed
Search for other papers by Margaret Boguszewski in
Google Scholar
PubMed
Search for other papers by Felipe F Casanueva in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
Search for other papers by Peter E Clayton in
Google Scholar
PubMed
Search for other papers by Catherine S Choong in
Google Scholar
PubMed
Search for other papers by David Clemmons in
Google Scholar
PubMed
Search for other papers by Mehul Dattani in
Google Scholar
PubMed
Search for other papers by Jan Frystyk in
Google Scholar
PubMed
Search for other papers by Ken Ho in
Google Scholar
PubMed
Search for other papers by Andrew R Hoffman in
Google Scholar
PubMed
Search for other papers by Reiko Horikawa in
Google Scholar
PubMed
Search for other papers by Anders Juul in
Google Scholar
PubMed
Search for other papers by John J Kopchick in
Google Scholar
PubMed
Search for other papers by Xiaoping Luo in
Google Scholar
PubMed
Search for other papers by Sebastian Neggers in
Google Scholar
PubMed
Search for other papers by Irene Netchine in
Google Scholar
PubMed
Search for other papers by Daniel S Olsson in
Google Scholar
PubMed
Search for other papers by Sally Radovick in
Google Scholar
PubMed
Search for other papers by Ron Rosenfeld in
Google Scholar
PubMed
Search for other papers by Richard J Ross in
Google Scholar
PubMed
Search for other papers by Katharina Schilbach in
Google Scholar
PubMed
Search for other papers by Paulo Solberg in
Google Scholar
PubMed
Search for other papers by Christian Strasburger in
Google Scholar
PubMed
Search for other papers by Peter Trainer in
Google Scholar
PubMed
Search for other papers by Kevin C J Yuen in
Google Scholar
PubMed
Search for other papers by Kerstin Wickstrom in
Google Scholar
PubMed
Search for other papers by Jens O L Jorgensen in
Google Scholar
PubMed
Search for other papers by on behalf of the Growth Hormone Research Society in
Google Scholar
PubMed
factor-I (IGF-I). Both are used diagnostically; IGF-I is used to monitor the effects of GH replacement in GH deficiency (GHD), and both GH and IGF-I are used in the diagnosis and management of acromegaly. While serum IGF-I level is used as a surrogate
Université Clermont Auvergne, Faculté de Médecine, Clermont-Ferrand, France
Search for other papers by Sylvain Roumeau in
Google Scholar
PubMed
Search for other papers by Joannice Thevenon in
Google Scholar
PubMed
CHU Clermont-Ferrand, Service de Biostatistiques, Clermont-Ferrand, France
Search for other papers by Lemlih Ouchchane in
Google Scholar
PubMed
CHU de Clermont-Ferrand, Service d’Endocrinologie, Diabétologie et Maladies Métaboliques, Clermont-Ferrand, France
Laboratoire GReD: UMR Université Clermont Auvergne-CNRS 6293, INSERM U1103, Clermont-Ferrand, France
Search for other papers by Salwan Maqdasy in
Google Scholar
PubMed
Laboratoire GReD: UMR Université Clermont Auvergne-CNRS 6293, INSERM U1103, Clermont-Ferrand, France
Search for other papers by Marie Batisse-Lignier in
Google Scholar
PubMed
CHU Clermont-Ferrand, Inserm CIC 1405, Clermont-Ferrand, France
Search for other papers by Christian Duale in
Google Scholar
PubMed
Université Clermont Auvergne, Inserm, Neuro-Dol, Clermont-Ferrand, France
CHU de Clermont-Ferrand, Service de chirurgie maxillo-faciale, Clermont-Ferrand, France
Search for other papers by Nathalie Pham Dang in
Google Scholar
PubMed
Search for other papers by Philippe Caron in
Google Scholar
PubMed
Université Clermont Auvergne, Faculté de Médecine, Clermont-Ferrand, France
Laboratoire GReD: UMR Université Clermont Auvergne-CNRS 6293, INSERM U1103, Clermont-Ferrand, France
Search for other papers by Igor Tauveron in
Google Scholar
PubMed
Université Clermont Auvergne, Inserm, Neuro-Dol, Clermont-Ferrand, France
Université Clermont Auvergne, Faculté de Chirurgie Dentaire, Clermont-Ferrand, France
Search for other papers by Laurent Devoize in
Google Scholar
PubMed
Introduction Oral and maxillofacial manifestations of acromegaly are hallmarks of the disease, including prognathism, inter-dental space enlargement (diastema), occlusion disorder (class III), temporo-mandibular joint pain, macroglossia and
Search for other papers by Anna-Pauliina Iivonen in
Google Scholar
PubMed
Search for other papers by Johanna Känsäkoski in
Google Scholar
PubMed
Search for other papers by Atte Karppinen in
Google Scholar
PubMed
Search for other papers by Leena Kivipelto in
Google Scholar
PubMed
Search for other papers by Camilla Schalin-Jäntti in
Google Scholar
PubMed
Search for other papers by Auli Karhu in
Google Scholar
PubMed
Search for other papers by Taneli Raivio in
Google Scholar
PubMed
inputs such as growth hormone-releasing hormone (GHRH) and somatostatin as well as several peripheral hormones. GH-secreting pituitary adenomas, i.e. somatotropinomas, lead to acromegaly in adults and (acro-) gigantism in children and adolescents
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), ISCIII, Spain
Department of Endocrinology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Department of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
Search for other papers by Susan M Webb in
Google Scholar
PubMed
Search for other papers by Jette Kristensen in
Google Scholar
PubMed
Search for other papers by Anna Nordenström in
Google Scholar
PubMed
Search for other papers by Diana Vitali in
Google Scholar
PubMed
Search for other papers by Vincent Amodru in
Google Scholar
PubMed
Search for other papers by Lenja Katharina Wiehe in
Google Scholar
PubMed
Search for other papers by Matt Bolz-Johnson in
Google Scholar
PubMed
identifying around half a dozen patients with either acromegaly, Addison’s disease or congenital adrenal hyperplasia and asked them to write down their experiences in a table template, initially created by EURORDIS, and reviewed and adapted by the authors for
School of Medicine, Western Sydney University, Sydney, Australia
Search for other papers by Prishila Fookeerah in
Google Scholar
PubMed
Westmead Clinical School, University of Sydney, Sydney, Australia
Search for other papers by Winny Varikatt in
Google Scholar
PubMed
Westmead Clinical School, University of Sydney, Sydney, Australia
Search for other papers by Meena Shingde in
Google Scholar
PubMed
Department of Neurosurgery, Westmead Hospital, Sydney, Australia
Search for other papers by Mark A J Dexter in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Sydney, Australia
Search for other papers by Mark McLean in
Google Scholar
PubMed
–132 years). Of the nine tumours, eight presented with acromegaly clinically. One tumour presented with visual field defects and only expressed gonadotrophins on immunostaining although without biochemical or clinical evidence of excess gonadotrophin